Investigation of molecular and cellular determinants of Immune Related Adverse Events following treatment with Immune Checkpoint Inhibitors

针对晚期、不治之症癌症的新型免疫疗法显著提高了患者的存活率。尽管这些治疗已被证明非常有效，但它们与严重的、有时危及生命的自身免疫性疾病的不可预测的发展有关。我们的目标是通过识别血液样本中的遗传风险因素和标志物来发现预测和潜在预防这些并发症的方法。如果成功，这将是癌症治疗方面的突破性进展。

Novel immune-based treatments for advanced, incurable, cancer have significantly improved patient survival. Although these treatments have proven highly effective, they are associated with the unpredictable development of severe and sometimes life-threatening autoimmune disease. We aim to discover ways to predict and potentially prevent these complications by identifying genetic risk factors and markers in blood samples. If successful, this will be a ground breaking advance in cancer care.